Plain-English translation of NCT04722978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a major research study testing whether adding moxifloxacin—an antibiotic that's already used to treat infections—can make standard chemotherapy work better for advanced triple-negative breast cancer. Half of the 228 patients will receive the two chemotherapy drugs (gemcitabine and carboplatin) plus moxifloxacin, while the other half will receive the same chemotherapy plus a placebo (a fake pill). The study will compare how well each group responds to treatment and track any side effects.
Triple-negative breast cancer is aggressive and hard to treat because it doesn't respond to common hormone-based therapies. Researchers believe this medication might boost the body's immune system to fight cancer more effectively when combined with chemotherapy, offering patients a better chance at slowing or stopping their disease.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy infusions on a regular schedule, plus either the new antibiotic or a placebo pill by mouth—but neither you nor your doctors will know which one you're getting until the study ends. You'll have blood tests and imaging scans to monitor how your cancer responds and watch for side effects. The study involves multiple clinic visits at one of several cancer centers participating in the trial.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China